tradingkey.logo
tradingkey.logo
Search

Janux Therapeutics Inc

JANX
Add to Watchlist
15.170USD
-0.410-2.63%
Close 07-31 16:00ETQuotes delayed by 15 min
925.13MMarket Cap
LossP/E TTM

JANX Income Statement

You can find the annual or quarterly income statement of Janux Therapeutics Inc here for insights into the performance and operational efficiency of Janux Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
Total revenue
--3.73M
--0.00
2177.90%10.00M
-100.00%0.00
-100.00%0.00
-100.00%0.00
-82.56%439.00K
741.72%8.90M
-38.87%1.25M
-13.50%2.46M
38.83%2.52M
-55.31%1.06M
28.89%2.05M
76.05%2.84M
56.43%1.81M
390.66%2.37M
318.16%1.59M
--1.62M
--1.16M
--482.00K
--380.00K
--0.00
--0.00
--0.00
--0.00
Revenue
--3.73M
--0.00
2177.90%10.00M
-100.00%0.00
-100.00%0.00
-100.00%0.00
-82.56%439.00K
741.72%8.90M
-38.87%1.25M
-13.50%2.46M
38.83%2.52M
-55.31%1.06M
28.89%2.05M
76.05%2.84M
56.43%1.81M
390.66%2.37M
318.16%1.59M
--1.62M
--1.16M
--482.00K
--380.00K
--0.00
--0.00
--0.00
--0.00
Operating expenses
8.74%37.95M
46.10%42.40M
24.72%45.25M
98.59%45.12M
62.97%34.90M
56.05%29.02M
97.93%36.28M
4.19%22.72M
-4.10%21.41M
-11.90%18.60M
-7.59%18.33M
11.10%21.80M
47.57%22.33M
39.75%21.11M
64.44%19.84M
191.45%19.63M
467.98%15.13M
812.75%15.11M
860.35%12.06M
508.86%6.73M
222.52%2.66M
--1.66M
--1.26M
--1.11M
--826.00K
R&D expenses
7.02%26.81M
51.63%31.55M
86.04%34.63M
132.68%34.66M
78.07%25.05M
69.97%20.81M
56.53%18.61M
-0.17%14.90M
-11.31%14.07M
-20.69%12.24M
-13.43%11.89M
5.95%14.92M
55.78%15.87M
38.19%15.43M
63.42%13.74M
197.36%14.09M
429.04%10.18M
1033.91%11.17M
907.91%8.41M
603.86%4.74M
250.64%1.93M
--985.00K
--834.00K
--673.00K
--549.00K
Depreciation, depletion, and amortization
-9.63%469.00K
-8.59%468.00K
-1.76%501.00K
6.92%541.00K
-2.44%519.00K
-3.58%512.00K
2.00%510.00K
7.43%506.00K
17.44%532.00K
31.76%531.00K
100.80%500.00K
336.11%471.00K
459.26%453.00K
529.69%403.00K
822.22%249.00K
730.77%108.00K
800.00%81.00K
611.11%64.00K
2600.00%27.00K
1200.00%13.00K
350.00%9.00K
--9.00K
--1.00K
--1.00K
--2.00K
Operating profit
1.96%-34.21M
-46.10%-42.40M
1.65%-35.25M
-226.42%-45.12M
-73.09%-34.90M
-79.85%-29.02M
-126.66%-35.84M
33.38%-13.82M
0.59%-20.16M
11.66%-16.14M
12.26%-15.81M
-20.20%-20.75M
-49.76%-20.28M
-35.40%-18.27M
-65.29%-18.02M
-176.09%-17.26M
-492.91%-13.54M
-715.11%-13.49M
-768.07%-10.90M
-465.28%-6.25M
-176.51%-2.28M
---1.66M
---1.26M
---1.11M
---826.00K
Net non-operating interest income (expenses)
Non-operating interest income
-13.50%9.85M
18.73%10.46M
40.54%10.94M
43.20%11.26M
110.87%11.39M
101.10%8.81M
83.35%7.78M
142.69%7.86M
91.39%5.40M
98.96%4.38M
220.14%4.25M
768.63%3.24M
2037.88%2.82M
2874.32%2.20M
867.88%1.33M
710.87%373.00K
--132.00K
--74.00K
--137.00K
--46.00K
----
----
----
----
----
Non-operating interest expense
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--109.00K
--97.00K
Special income (expenses)
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
100.00%0.00
100.00%0.00
--0.00
----
---1.25M
---490.00K
Other non-operating income (expenses)
--9.85M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income before tax
-3.63%-24.36M
-58.02%-31.95M
13.35%-24.31M
-468.18%-33.86M
-59.27%-23.51M
-71.93%-20.22M
-142.56%-28.06M
65.96%-5.96M
15.46%-14.76M
26.81%-11.76M
30.71%-11.57M
-3.67%-17.51M
-30.19%-17.46M
-19.75%-16.07M
-55.08%-16.70M
-172.12%-16.89M
-487.13%-13.41M
-710.63%-13.42M
-757.17%-10.77M
-152.28%-6.21M
-61.64%-2.28M
---1.66M
---1.26M
---2.46M
---1.41M
Income tax
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income after tax
-3.63%-24.36M
-58.02%-31.95M
13.35%-24.31M
-468.18%-33.86M
-59.27%-23.51M
-71.93%-20.22M
-142.56%-28.06M
65.96%-5.96M
15.46%-14.76M
26.81%-11.76M
30.71%-11.57M
-3.67%-17.51M
-30.19%-17.46M
-19.75%-16.07M
-55.08%-16.70M
-172.12%-16.89M
-487.13%-13.41M
-710.63%-13.42M
-757.17%-10.77M
-152.28%-6.21M
-61.64%-2.28M
---1.66M
---1.26M
---2.46M
---1.41M
Net income from continuous operations
-3.63%-24.36M
-58.02%-31.95M
13.35%-24.31M
-468.18%-33.86M
-59.27%-23.51M
-71.93%-20.22M
-142.56%-28.06M
65.96%-5.96M
15.46%-14.76M
26.81%-11.76M
30.71%-11.57M
-3.67%-17.51M
-30.19%-17.46M
-19.75%-16.07M
-55.08%-16.70M
-172.12%-16.89M
-487.13%-13.41M
-710.63%-13.42M
-757.17%-10.77M
-152.28%-6.21M
-61.64%-2.28M
---1.66M
---1.26M
---2.46M
---1.41M
Net income attributable to controlling interests
-3.63%-24.36M
-58.02%-31.95M
13.35%-24.31M
-468.18%-33.86M
-59.27%-23.51M
-71.93%-20.22M
-142.56%-28.06M
65.96%-5.96M
15.46%-14.76M
26.81%-11.76M
30.71%-11.57M
-3.67%-17.51M
-30.19%-17.46M
-19.75%-16.07M
-55.08%-16.70M
-172.12%-16.89M
-487.13%-13.41M
-710.63%-13.42M
-757.17%-10.77M
-152.28%-6.21M
-61.64%-2.28M
---1.66M
---1.26M
---2.46M
---1.41M
Net income attributable to common shareholders
-3.63%-24.36M
-58.02%-31.95M
13.35%-24.31M
-468.18%-33.86M
-59.27%-23.51M
-71.93%-20.22M
-142.56%-28.06M
65.96%-5.96M
15.46%-14.76M
26.81%-11.76M
30.71%-11.57M
-3.67%-17.51M
-30.19%-17.46M
-19.75%-16.07M
-55.08%-16.70M
-172.12%-16.89M
-487.13%-13.41M
-710.63%-13.42M
-757.17%-10.77M
-152.28%-6.21M
-61.64%-2.28M
---1.66M
---1.26M
---2.46M
---1.41M
Basic earnings per share
-2.18%-0.39
-44.57%-0.51
23.68%-0.39
-399.78%-0.55
-26.43%-0.38
-41.26%-0.36
-102.95%-0.51
73.85%-0.11
28.02%-0.30
34.84%-0.25
37.05%-0.25
-2.71%-0.42
-28.79%-0.42
-19.85%-0.39
-55.40%-0.40
-173.19%-0.41
-467.05%-0.32
-677.05%-0.32
-721.89%-0.26
-141.91%-0.15
-61.65%-0.06
---0.04
---0.03
---0.06
---0.04
Diluted earnings per share
-2.18%-0.39
-44.57%-0.51
23.68%-0.39
-399.78%-0.55
-26.43%-0.38
-41.26%-0.36
-102.95%-0.51
73.85%-0.11
28.02%-0.30
34.84%-0.25
37.05%-0.25
-2.71%-0.42
-28.79%-0.42
-19.85%-0.39
-55.40%-0.40
-173.19%-0.41
-467.05%-0.32
-677.05%-0.32
-721.89%-0.26
-141.91%-0.15
-61.65%-0.06
---0.04
---0.03
---0.06
---0.04
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Janux Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing JANX stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Janux Therapeutics Inc's revenue at year end?

Janux Therapeutics Inc reported 10.00M in revenue for fiscal year 2025, up from 10.59M in the previous year.

What was Janux Therapeutics Inc's net income for the year?

Janux Therapeutics Inc posted -113.62M in net income for fiscal year 2025.

How much net income did Janux Therapeutics Inc post in the last quarter?

Janux Therapeutics Inc reported -24.36M in net income for the latest quarter。

What was Janux Therapeutics Inc's annual operating profit?

Janux Therapeutics Inc's operating income was -157.67M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.